Literature DB >> 26684631

Allopurinol-induced Sweet's syndrome.

G Polimeni1, R Cardillo2, E Garaffo2, C Giardina3, R Macrì3, V Sirna3, C Guarneri4, V Arcoraci5.   

Abstract

Sweet's syndrome, or acute febrile neutrophilic dermatosis, is an uncommon severe cutaneous condition, not previously associated with allopurinol therapy. We describe the case of an 87-year-old woman with hyperuricemia who developed classic Sweet's syndrome manifestations 8 days after being treated with allopurinol. Patient's symptoms included fever, painful edema in the hands and lower limbs with non-pruritic erythematous plaques topped by pus-filled skin blisters, right eye conjunctivitis, splenomegaly and joint pain. At the emergency department, blood tests showed neutrophilic leukocytosis, inflammatory state and altered liver function. During hospitalization, she received unsuccessful treatments with two different antibiotics (namely ceftriaxone and levofloxacin), while treatment with intravenous methylprednisolone produced a rapid clinical remission of symptoms, cutaneous lesion pain improvement, normalization of her body temperature and her blood values returned to normal. Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship between the patient's development of Sweet's syndrome and allopurinol therapy. Because the signs and symptoms of Sweet's syndrome resemble an infectious process, the correct diagnosis may be delayed and inappropriate treatment regimen with antibiotics may often precede glucocorticoid therapy.
© The Author(s) 2015.

Entities:  

Keywords:  acute febrile neutrophilic dermatosis; adverse drug reactions; allopurinol; cutaneous manifestation; drug-induced Sweet’s syndrome

Mesh:

Substances:

Year:  2015        PMID: 26684631      PMCID: PMC5806712          DOI: 10.1177/0394632015599705

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  12 in total

Review 1.  The extracutaneous involvement in the neutrophilic dermatoses.

Authors:  M D Vignon-Pennamen
Journal:  Clin Dermatol       Date:  2000 May-Jun       Impact factor: 3.541

2.  AN ACUTE FEBRILE NEUTROPHILIC DERMATOSIS.

Authors:  R D SWEET
Journal:  Br J Dermatol       Date:  1964 Aug-Sep       Impact factor: 9.302

3.  Sweet's syndrome after adalimumab therapy for refractory relapsing polychondritis.

Authors:  Sarah Keidel; Aubretia McColl; Sally Edmonds
Journal:  BMJ Case Rep       Date:  2011-12-21

Review 4.  Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome.

Authors:  D C Walker; P R Cohen
Journal:  J Am Acad Dermatol       Date:  1996-05       Impact factor: 11.527

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 6.  Neutrophilic dermatoses.

Authors:  Jeffrey P Callen
Journal:  Dermatol Clin       Date:  2002-07       Impact factor: 3.478

Review 7.  Sweet's syndrome (acute febrile neutrophilic dermatosis)

Authors:  P von den Driesch
Journal:  J Am Acad Dermatol       Date:  1994-10       Impact factor: 11.527

8.  Sweet's syndrome associated with G-CSF.

Authors:  S Paydaş; B Sahin; E Seyrek; M Soylu; G Gonlusen; A Acar; I Tuncer
Journal:  Br J Haematol       Date:  1993-09       Impact factor: 6.998

9.  Severe hypersensitivity reactions to allopurinol.

Authors:  P G Lang
Journal:  South Med J       Date:  1979-11       Impact factor: 0.954

Review 10.  Drug-induced Sweet's syndrome.

Authors:  Dennis F Thompson; Kristin E Montarella
Journal:  Ann Pharmacother       Date:  2007-04-10       Impact factor: 3.154

View more
  3 in total

Review 1.  Insights Into the Pathogenesis of Sweet's Syndrome.

Authors:  Michael S Heath; Alex G Ortega-Loayza
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

2.  Sweet's Syndrome (SS) in the Course of Acute Myeloid Leukaemia (AML).

Authors:  Claudio Guarneri; Uwe Wollina; Torello Lotti; Georgi Konstantinov Maximov; Ilia Lozev; Serena Gianfaldoni; Ivan Pidakev; Jacopo Lotti; Georgi Tchernev
Journal:  Open Access Maced J Med Sci       Date:  2018-01-13

3.  Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study.

Authors:  Claudia Giardina; Paola M Cutroneo; Eleonora Mocciaro; Giuseppina T Russo; Giuseppe Mandraffino; Giorgio Basile; Franco Rapisarda; Rosarita Ferrara; Edoardo Spina; Vincenzo Arcoraci
Journal:  Front Pharmacol       Date:  2018-04-11       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.